NCT02480777

Brief Summary

The primary purpose of this research study is to determine the safety of injecting ones own Schwann cells as a supplement along with nerve autograft (eg sural nerve) a few weeks after a severe injury to the sciatic nerve has occurred.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 21, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 25, 2015

Completed
Last Updated

March 5, 2019

Status Verified

March 1, 2019

First QC Date

June 21, 2015

Last Update Submit

March 4, 2019

Conditions

Interventions

Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
\- single patient with severe sciatic nerve injury enrolled under emergency request

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

University of Miami Miller School of Medicine

Miami, Florida, 33136, United States

Location

Study Officials

  • Allan Levi, MD, PhD

    University of Miami

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
expanded access
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor of Neurosurgery

Study Record Dates

First Submitted

June 21, 2015

First Posted

June 25, 2015

Last Updated

March 5, 2019

Record last verified: 2019-03

Locations